Panacea Biotec Ltd
NSE: PANACEABIO · Pharmaceuticals · sector
₹306.75NSE close 2026-10-26
Key numbers
Market cap₹1,880 cr
Price₹306.75
52w high / low₹647 / ₹292
P/E–Sector median 27.9x
P/B2.2xSector median 2.9x
Book value₹136.2
Dividend yield–Sector median 0.48%
ROE-0.8%Sector median 11.7%
ROCE-0.5%Sector median 12.3%
OPM1.9%Sector median 14.0%
Debt / equity0.03xSector median 0.16x
EV/EBITDA139.6xSector median 18.6x
Interest cover-0.6x
Current ratio1.47x
Sales growth 3y+11.6%Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹74 cr vs borrowings ₹24 cr (FY26): cash is higher (net cash).
- Borrowings rose in each of the last 3 years (₹20 cr → ₹24 cr).
- Operating profit covered interest -0.6x in the last 12 months.
- No promoter shares are pledged.
- Operating cash flow was below net profit in 3 of the last 5 years (FY25, FY23, FY22).
- Net loss in 2 of the last 8 quarters.
- Revenue was higher than a year earlier in 3 of the last 4 quarters.
- No dividend in the last 5 financial years.
- Price ₹306.75 on 2026-10-26: -52.6% from the 52-week high, +4.9% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹607.75 · low ₹277.30
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 147 | 163 | 133 | 167 | 141 | 165 | 167 | 200 |
| EBITDA | 10 | 11 | 1 | 10 | -15 | 15 | 5 | 8 |
| OPM % | 6.6% | 6.6% | 0.6% | 6.1% | -10.7% | 8.8% | 3.2% | 4.2% |
| Other income | 5 | 4 | 9 | 6 | 6 | 2 | 3 | 4 |
| Net profit | 5 | 5 | -2 | 4 | -14 | 4 | 1 | 2 |
| EPS (₹) | 0.77 | 0.74 | -0.31 | 0.66 | -2.27 | 0.65 | 0.08 | 0.38 |
| Revenue YoY | -4.2% | +1.0% | +25.8% | +19.7% | ||||
| Profit YoY | -390.0% | -11.9% | – | -43.2% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 661 | 460 | 559 | 559 | 640 | 673 |
| EBITDA | 1,662 | 5 | 16 | 10 | 15 | 13 |
| Net profit | 1,078 | -34 | -1 | -8 | -5 | -7 |
| EPS (₹) | 175.98 | -5.51 | -0.19 | -1.37 | -0.88 | -1.16 |
| Revenue growth | -30.4% | +21.6% | -0.0% | +14.4% | +10.3% | |
| Profit growth | -103.1% | – | – | – | -162.0% | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +11.6% | +0.5% | +10.3% |
| Net profit | – | – | -162.0% |
| EPS | – | – | – |
| Share price | – | +2.0% (2y) | -23.5% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 844 | 842 | 835 | 835 |
| Borrowings | – | 20 | 21 | 22 | 24 |
| Cash & equivalents | – | 239 | 180 | 110 | 74 |
| Total assets | – | 1,271 | 1,241 | 1,290 | 1,262 |
| Fixed assets | – | 588 | 560 | 543 | 553 |
| Capital work in progress | – | 28 | 75 | 94 | 100 |
| Investments | – | 0 | 0 | 0 | 0 |
| Receivables | – | 60 | 57 | 73 | 74 |
| Inventory | – | 202 | 178 | 214 | 193 |
| Payables | – | 177 | 154 | 226 | 190 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | -108 | -423 | -0 | -27 | 17 |
| Cash from investing | 1,283 | 430 | 10 | 65 | -40 |
| Cash from financing | -1,176 | -18 | -3 | -3 | -1 |
| Capex | 13 | 41 | 78 | 50 | 54 |
| Free cash flow | -121 | -464 | -78 | -78 | -37 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | -4.0% | -0.1% | -1.0% | -0.6% |
| ROCE % | – | 2.0% | 0.6% | -0.5% | -0.2% |
| Debtor days | – | 48 | 37 | 47 | 42 |
| Inventory days | – | 292 | 282 | 391 | 251 |
| Payable days | – | 256 | 244 | 413 | 247 |
| Cash conversion cycle (days) | – | 84 | 75 | 25 | 46 |
| Working capital days | – | 185 | 115 | 116 | 94 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 72.48% |
| FIIs | 2.75% |
| DIIs | 2.47% |
| of which Mutual funds | 0.00% |
| Public (non-institutions) | 22.30% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 72.49% | 72.48% | 72.48% | 72.48% | 72.48% | 72.48% | 72.48% | 72.48% |
| Promoter group | % |
|---|---|
| Dr. Rajesh Jain | 49.01% |
| Mr. Sandeep Jain | 15.27% |
| Mrs. Nirmala Jain | 4.10% |
| First Lucre Partnership Co. | 3.68% |
| Rajesh Jain (HUF)** (Karta : Rajesh Jain) | 0.33% |
| Second Lucre Partnership Co. | 0.09% |
| Mrs. Meena Jain | 0.00% |
| Mrs. Pamilla Jain | 0.00% |
| Mr. Ankesh Jain | 0.00% |
| Mr. Harshet Jain | 0.00% |
| Mrs. Priyanka Jain | 0.00% |
| Sandeep Jain (HUF) (Karta : Sandeep Jain) | 0.00% |
| Mr. Abhey Kumar Jain | 0.00% |
| Mr. Ashish Jain | 0.00% |
| Public holders above 1% | % |
|---|---|
| Massachusetts Institute of Technology | 1.81% |
| Viral Amal Parikh | 1.47% |
32,961 shareholders. Pledged: 0.00% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| PANACEABIO | ₹1,880 cr | – | 2.2x | -0.8% | -0.5% | 1.9% | +11.6% | – |
Business segments (FY26)
| Segment | Revenue | Share | EBIT | Margin |
|---|---|---|---|---|
| Vaccines | ₹410 cr | 64.1% | ₹-27 cr | -6.5% |
| Formulations | ₹230 cr | 35.9% | ₹20 cr | 8.5% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2024-09-19 | Other | Annual General Meeting |
| 2023-09-21 | Other | Annual General Meeting |
| 2022-09-19 | Other | Annual General Meeting |
| 2021-09-16 | Other | Annual General Meeting |
| 2020-12-15 | Other | Annual General Meeting |
| 2020-09-21 | Restructuring | Demerger |
| 2019-09-19 | Other | Annual General Meeting |
| 2018-09-19 | Other | Annual General Meeting |
| 2017-09-18 | Other | Annual General Meeting |
| 2016-09-22 | Other | Annual General Meeting |
| 2015-09-22 | Other | Annual General Meeting |
| 2014-09-17 | Other | Annual General Meeting |
| 2013-09-17 | Other | Annual General Meeting |
| 2012-09-20 | Other | Annual General Meeting |
| 2011-09-19 | Dividend | Annual General Meeting And Dividend Re.0.75 Per Share |
| 2010-09-16 | Dividend | Annual General Meeting And Dividend Re.0.25 Per Share |
| 2009-09-18 | Other | Annual General Meeting |
| 2008-09-19 | Dividend | Agm/Dividend - 100% |
| 2007-09-21 | Dividend | Agm/Dividend-100% |
| 2006-09-22 | Dividend | Agm/Dividend-100% |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Pharmaceuticals: Manufacturing of pharmaceuticals, medicinal, chemical and botanical products
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | PANACEABIO |
| BSE code | 531349 |
| ISIN | INE922B01023 |
| Face value | ₹1.0 |
| Incorporated | 1984-02-02 |
| Website | www.panaceabiotec.com |
| Plants (India / abroad) | 3 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.